EADO 2020 | Combination radiotherapy + checkpoint blockade in patients with advanced melanoma

Michael Postow, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the results of a Phase I study evaluating radiotherapy in combination with nivolumab and ipilimumab in advanced, stage IV melanoma patients with the primary objective being the safety of this combined modality treatment. Radiotherapy with nivolumab and ipilimumab was shown to be safe when compared to blockade therapy alone, and in irradiated metastases, there was no disease progression, suggesting that combining radiotherapy with immune checkpoint blockade may be a feasible approach to improve outcomes in patients with advanced melanoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).